Drugs for bad bugs: confronting the challenges of antibacterial discovery

House of Lords Select Committee on Science and Technology Seventh Report. Resistance to Antibiotics and Other Antimicrobial Agents [online] , (Stationary Office, London, UK, 1998).

Shlaes, D. M. et al. Antibiotic discovery: state of the state. ASM News 70, 275–281 (2004).

Talbot, G. H. et al. Bad bugs need drugs: an update on the development pipeline from the antibacterial availability task force of the IDSA. Clin. Infect. Dis. 42, 657–668 (2006).

Wenzel, R. P. The antibiotic pipeline — challenges, costs, and values. N. Engl. J. Med. 351, 523–526 (2004).

Infectious Disease Society of America. Bad Bugs, No Drugs [online] , (2004). Seminal review by key opinion leaders on the shrinking investment by big pharma in antibacterial discovery, and the growing challenge of resistant pathogens.

Tickell, S. The Antibiotic Innovation Study: Expert Voices on a Critical Need [online] , (2005).

Nathan, C. Antibiotics at the cross roads. Nature 431, 899–902 (2004).

Kaplan, W. & Laing, R. Priority Medicines for Europe and the World [online] , (World Health Organization, Geneva, 2004).

Brown, J. R. & Warren, P. V. Antibiotic discovery: is it in the genes? Drug Discov. Today 3, 564–566 (1998).

Chan, P. F., Macarron, R., Payne, D. J., Zalacain, M. & Holmes, D. J. Novel antibacterials: a genomics approach to drug discovery. Curr. Drug Targets — Infect. Dis. 2, 109–119 (2002).

Chan, P. F. et al. Characterization of a noval fucose-regulated promoter (PfcsK) suitable for gene essentiality and antibacterial mode of action studies in Streptococcus pneumoniae. J. Bacteriol. 185, 2051–2058 (2003).

Zhang, L. et al. Regulated gene expression in Staphylococcus aureus for identifying conditional lethal phenotypes and antibiotic mode of action. Gene 255, 297–305 (2000).

Yin, D. et al. Identification of Antimicrobial targets using a comprehensive genomic approach. Pharmacogenomics 5, 101–113 (2004).

Zalacain, M. et al. A global approach to identify novel broad-spectrum antibacterial targets among proteins of unknown function. J. Mol. Microbiol. Biotechnol. 6, 109–126 (2003).

Jarvest, R. L., et al. Nanomolar inhibitors of Staphylococcus aureus methionyl tRNA synthetase with potent antibacterial activity against Gram-positive pathogens. J. Med. Chem. 45, 1959–1962 (2002).

Payne, D. J. et al. Discovery of a novel and potent class of FabI directed antibacterial agents. Antimicrob. Agents Chemother. 46, 3118–3124 (2002).

Fan, F. et al. Defining and combating the mechanisms of triclosan resistance in clinical isolates of Staphylococcus aureus. Antimicrob. Agents Chemother. 46, 3343–3347 (2002).

Aubert, K. & Zalacain, M. 3 Peptide deformylase inhibitors. Prog. Med. Chem. 44, 109–143 (2006).

Gentry, D. R. et al. Variable sensitivity to bacterial methionyl-tRNA synthetase inhibitors reveals subpopulations of Streptococcus pneumoniae with two distinct methionyl-tRNA synthetase genes. Antimicrob. Agents Chemother. 47, 1784–1789 (2003). An example illustrating the risk associated with exploitation of non-clinically validated targets for antibacterial discovery.

Du, W. et al. Two active forms of UDP-N-acetylglucosamine enolpyruvyl transferase in Gram-positive bacteria. J. Bacteriol. 182, 4146–4152 (2000).

Heath, R. J. & Rock, C. O. A triclosan-resistant bacterial enzyme. Nature 406, 145 (2000).

Payne, D. J., Gwynn, M. N., Holmes, D. J. & Rosenberg, M. Genomic approaches to antibacterial discovery. Methods Mol. Biol. 266, 231–259 (2004).

Andries, K. et al. A diarylquinoline drug active on the ATP synthase of Mycobacterium tuberculosis. Science 307, 223–227 (2005).

Heerding, D. A. et al. New benzylidenethiazolidine-doines as antibacterial agents. Bioorg. Med. Chem. Lett. 13, 3771–3773 (2003).

Chan, P. F. et al. Finding the gems using genomic discovery: antibacterial drug discovery strategies — the successes and the challenges. Drug Discov. Today: Ther. Strategies 1, 519–527 (2004)

Pace, N. R. A molecular view of microbial diversity and the biosphere. Science 276, 734 (1997).

Wong, K. K. et al. Engineering a cell-free murein biosynthetic pathway: combinatorial enzymology in drug discovery. J. Am. Chem. Soc. 120, 13527–13528 (1998).

DeVito, J. A. et al. An array of target-specific screening strains for antibacterials discovery. Nature Biotechnol. 20, 478–483 (2002).

Wong, K. K. & Pompliano, D. L. in Resolving the Antibiotic Paradox: Progress in Understanding Drug Resistance and Development of New Antibiotics (eds Rosen, B. P. & Mobashery, S.) (Plenum, New York, 1999)

Feher, M. & Schmidt, J. M. Property distributions: differences between drugs, natural products, and molecules from combinatorial chemistry. J. Chem. Inf. Comput. Sci. 43, 218–227 (2003).

Lipinski, C. A., Lombardo, F., Dominy, B. W. & Feeney, P. J. Experimental and computional approaches to estimate solubility and permeability in drug discovery and development settings. Adv. Drug Deliv. Rev. 23, 3–25 (1997).

Walsh, C. T. Combinatorial biosynthesis of antibiotics: challenges and opportunities. Chembiochem 3, 125–134 (2002)

Throup, J. P. et al. A genomic analysis of two-component signal transduction in Streptococcus pneumoniae. Mol. Microbiol. 35, 566–576 (2000).

Ji. Y. et al. Identification of critical staphylococcal genes using conditional phenotypes generated by antisense RNA. Science 293, 2266–2269 (2001)